menu
    • menu
    [{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Beijing Aosaikang Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"$11.4 million","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Small molecule","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Ferric Maltol","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"Shield Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Shield Therapeutics \/ Beijing Aosaikang Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Shield Therapeutics \/ Beijing Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Ferric Pyrophosphate Citrate","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Rockwell Medical \/ Sun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Rockwell Medical \/ Sun Pharma"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"China Medical System","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"INDIA","productType":"Small molecule","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Desidustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Phase III","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ China Medical System","highestDevelopmentStatusID":"10","companyTruncated":"Zydus Lifesciences \/ China Medical System"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"SOUTH KOREA","productType":"Large molecule","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Eculizumab","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Not Applicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"U.S.A","productType":"Large molecule","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Dova Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Dova Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dova Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dova Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Wanbury Limited","sponsor":"Cipla","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"INDIA","productType":"Small molecule","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"Folic Acid","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Wanbury Limited","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Wanbury Limited \/ Cipla","highestDevelopmentStatusID":"12","companyTruncated":"Wanbury Limited \/ Cipla"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"CSL Vifor","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"GERMANY","productType":"Small molecule","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fresenius Kabi AG \/ Vifor Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius Kabi AG \/ Vifor Pharma"},{"orgOrder":0,"company":"Domainex","sponsor":"LUNAC Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Undisclosed","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Protease","graph1":"Hematology","graph2":"Discovery","graph3":"Domainex","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Domainex \/ LUNAC Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Domainex \/ LUNAC Therapeutics"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Not Applicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"U.S.A","productType":"Large molecule","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Apamistamab-I-131","moa":"CD45","graph1":"Hematology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"MGTA-145","moa":"CXCR2","graph1":"Hematology","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Magenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"CANADA","productType":"Small molecule","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"BCX9930","moa":"Complement Factor D","graph1":"Hematology","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst Pharmaceuticals \/ Not Applicable "},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Patisiran","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Alnylam Pharmaceuticals \/ Gen","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Pharmaceuticals \/ Gen"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Not Applicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"U.S.A","productType":"Large molecule","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Activated Marzeptacog Alfa","moa":"","graph1":"Hematology","graph2":"Phase II","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catalyst Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Catalyst Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"JAPAN","productType":"Large molecule","date":"April 2020","year":"2020","type":"Termination","leadProduct":"Human fibrinogen","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0.40000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0.40000000000000002,"dosageForm":"Patch","sponsorNew":"Takeda Pharmaceutical \/ Johnson & Johnson","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Johnson & Johnson"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Laboratori Derivati Organici","sponsor":"Cerus DMCC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"Heparin Sodium","moa":"Factor IIa","graph1":"Hematology","graph2":"Undisclosed","graph3":"Laboratori Derivati Organici","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Laboratori Derivati Organici \/ Cerus DMCC","highestDevelopmentStatusID":"1","companyTruncated":"Laboratori Derivati Organici \/ Cerus DMCC"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CTX001","moa":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ferric Citrate","moa":"TfR1","graph1":"Hematology","graph2":"Phase III","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Peptide","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ FibroGen"},{"orgOrder":0,"company":"Shanghai Cell Therapy Group","sponsor":"Baize Plan Fund","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"CHINA","productType":"Cell and Gene therapy","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Hematopoietic stem cells","moa":"","graph1":"Hematology","graph2":"Undisclosed","graph3":"Shanghai Cell Therapy Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Cell Therapy Group \/ Baize Plan Fund","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Cell Therapy Group \/ Baize Plan Fund"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Mepolizumab","moa":"IL-5","graph1":"Hematology","graph2":"Approved","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"rNAPc2","moa":"Tissue factor","graph1":"Hematology","graph2":"Preclinical","graph3":"ARCA Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ARCA Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MGTA-145","moa":"CXCR2","graph1":"Hematology","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"JonesTrading Institutional Services","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"rNAPc2","moa":"Tissue factor","graph1":"Hematology","graph2":"Preclinical","graph3":"ARCA Biopharma","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0.01,"dosageForm":"","sponsorNew":"ARCA Biopharma \/ JonesTrading Institutional Services","highestDevelopmentStatusID":"4","companyTruncated":"ARCA Biopharma \/ JonesTrading Institutional Services"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Achillion","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"$930.0 million","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"Danicopan","moa":"Factor D","graph1":"Hematology","graph2":"Phase III","graph3":"Achillion","amount2":0.93000000000000005,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0.93000000000000005,"dosageForm":"Oral","sponsorNew":"Achillion \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Achillion \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin-associated serine protease 2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Not Applicable"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Anthos Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Abelacimab","moa":"Factor XI","graph1":"Hematology","graph2":"Undisclosed","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ Anthos Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Lonza Group \/ Anthos Therapeutics"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ FibroGen"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blood Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ Astellas Pharma","highestDevelopmentStatusID":"12","companyTruncated":"FibroGen \/ Astellas Pharma"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ferric Citrate","moa":"TfR1","graph1":"Hematology","graph2":"Phase IV","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Hematology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin-associated serine protease 2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"EDIT-301","moa":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blood Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Not Applicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Coagulation factor Xa (recombinant), inactivated-zhzo","moa":"Factor Xa","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":1.3999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":1.3999999999999999,"dosageForm":"","sponsorNew":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals, Inc.","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals, Inc."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Luspatercept","moa":"TGF beta","graph1":"Hematology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Azzur Group","sponsor":"Editas Medicine","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"EDIT-301","moa":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Azzur Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Azzur Group \/ Editas Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Azzur Group \/ Editas Medicine"},{"orgOrder":0,"company":"VarmX","sponsor":"Ysios Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"July 2020","year":"2020","type":"Series B Financing","leadProduct":"VMX-COO1","moa":"Factor Xa","graph1":"Hematology","graph2":"Undisclosed","graph3":"VarmX","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"VarmX \/ Ysios Capital","highestDevelopmentStatusID":"1","companyTruncated":"VarmX \/ Ysios Capital"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ciraparantag","moa":"","graph1":"Hematology","graph2":"Phase II","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"AMAG Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AMAG Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Norgine","pharmaFlowCategory":"D","upfrontCash":"$30.0 million","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Ciraparantag","moa":"","graph1":"Hematology","graph2":"Phase II","graph3":"AMAG Pharmaceuticals","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.28999999999999998,"dosageForm":"","sponsorNew":"AMAG Pharmaceuticals \/ Norgine B.V","highestDevelopmentStatusID":"8","companyTruncated":"AMAG Pharmaceuticals \/ Norgine B.V"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"Coagulation factor Xa (recombinant), inactivated-zhzo","moa":"Factor Xa","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":1.3999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":1.3999999999999999,"dosageForm":"","sponsorNew":"Alexion Pharmaceuticals \/ Alexion","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Pharmaceuticals \/ Alexion"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BCX9930","moa":"Complement Factor D","graph1":"Hematology","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"rNAPc2","moa":"Tissue factor","graph1":"Hematology","graph2":"Preclinical","graph3":"ARCA Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ARCA Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX-R18","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"EDIT-301","moa":"CD34+ gene","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"OMS906","moa":"MBL-associated serine protease","graph1":"Hematology","graph2":"Phase I","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Omeros \/ Not Applicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BCX9930","moa":"Complement Factor D","graph1":"Hematology","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"Factor B","graph1":"Hematology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Not Applicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Corza","pharmaFlowCategory":"D","upfrontCash":"427.0 million","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"September 2020","year":"2020","type":"Divestment","leadProduct":"Human Fibrinogen","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0.42999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0.42999999999999999,"dosageForm":"Patch","sponsorNew":"Takeda Pharmaceutical \/ Corza","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Corza"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"eXIthera Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"EP-7041","moa":"Factor XIa","graph1":"Hematology","graph2":"Phase I","graph3":"eXIthera Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"eXIthera Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"eXIthera Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Mepolizumab","moa":"IL-5","graph1":"Hematology","graph2":"Approved","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Covis Pharma","pharmaFlowCategory":"D","upfrontCash":"$647.0 million","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"Ferumoxytol","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"AMAG Pharmaceuticals","amount2":0.65000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0.65000000000000002,"dosageForm":"Intravenous Injection","sponsorNew":"AMAG Pharmaceuticals \/ Covis","highestDevelopmentStatusID":"12","companyTruncated":"AMAG Pharmaceuticals \/ Covis"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Luspatercept","moa":"TGF beta","graph1":"Hematology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BCX9930","moa":"Complement Factor D","graph1":"Hematology","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imago BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Bentracimab","moa":"P2Y12 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"Sidero Bioscience","sponsor":"SRS Life Sciences Pte ltd","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"FTH1","moa":"","graph1":"Hematology","graph2":"Undisclosed","graph3":"Sidero Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Sidero Bioscience \/ SRS Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Sidero Bioscience \/ SRS Life Sciences"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blood Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin-associated serine protease 2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Not Applicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"OMS906","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Omeros \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ FibroGen"},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin-associated serine protease 2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Not Applicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ Astellas Pharma","highestDevelopmentStatusID":"12","companyTruncated":"FibroGen \/ Astellas Pharma"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"FibroGen","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ FibroGen"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Luspatercept","moa":"TGF beta","graph1":"Hematology","graph2":"Approved","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acceleron Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Peptide","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Covis Pharma","pharmaFlowCategory":"D","upfrontCash":"$647.0 million","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"November 2020","year":"2020","type":"Acquisition","leadProduct":"Ferumoxytol","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"AMAG Pharmaceuticals","amount2":0.65000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0.65000000000000002,"dosageForm":"","sponsorNew":"AMAG Pharmaceuticals \/ Covis Group","highestDevelopmentStatusID":"12","companyTruncated":"AMAG Pharmaceuticals \/ Covis Group"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Hematology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ciraparantag","moa":"","graph1":"Hematology","graph2":"Phase II","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Covis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Covis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Iodine-131 apamistamab","moa":"CD45","graph1":"Hematology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ FibroGen"},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin-associated serine protease 2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Not Applicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blood Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Human Fibrinogen","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Octapharma \/ Not Applicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Not Applicable"},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"RTW Investments","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"December 2020","year":"2020","type":"Series D Financing","leadProduct":"Polysaccharide iron complex","moa":"CIAO2B","graph1":"Hematology","graph2":"Approved","graph3":"Nuance Pharma","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0.17999999999999999,"dosageForm":"Capsule","sponsorNew":"Nuance Pharma \/ RTW Investments","highestDevelopmentStatusID":"12","companyTruncated":"Nuance Pharma \/ RTW Investments"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Peptide","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Apellis","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Apellis"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"Factor B","graph1":"Hematology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"WuXi Biologics","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"CAN106","moa":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"CANbridge Pharmaceuticals \/ WuXi Biologics","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge Pharmaceuticals \/ WuXi Biologics"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"FibroGen","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ FibroGen"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Not Applicable"},{"orgOrder":0,"company":"Caplin Point Laboratories Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Argatroban","moa":"Thrombin","graph1":"Hematology","graph2":"Approved","graph3":"Caplin Point Laboratories Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caplin Point Laboratories Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Caplin Point Laboratories Limited \/ Not Applicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Carglumic Acid","moa":"CPS1","graph1":"Hematology","graph2":"Approved","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati Rare Diseases \/ Not Applicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin-associated serine protease 2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Not Applicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Voxelotor","moa":"Hemoglobin subunit alpha","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral suspension","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blood Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"BGE-117","moa":"HIF-PH","graph1":"Hematology","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioAge Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Not Applicable"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Approved","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmacosmos AS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmacosmos AS \/ Not Applicable"},{"orgOrder":0,"company":"Biovectra Inc","sponsor":"PhaseBio Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"Bentracimab","moa":"P2Y12 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Biovectra Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Biovectra Inc \/ PhaseBio Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Biovectra Inc \/ PhaseBio Pharmaceuticals"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"WuXi Biologics","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"CAN106","moa":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"CANbridge Pharmaceuticals \/ Wuxi Biologics","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge Pharmaceuticals \/ Wuxi Biologics"},{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Ferric Maltol","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Shield Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shield Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shield Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Peptide","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"BCX9930","moa":"Complement Factor D","graph1":"Hematology","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Human fibrinogen","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Not Applicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Not Applicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blood Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"C5 complement","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ FibroGen"},{"orgOrder":0,"company":"Versiti","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Heparin Sodium","moa":"Antithrombin III","graph1":"Hematology","graph2":"Phase III","graph3":"Versiti","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Versiti \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Versiti \/ National Institutes of Health"},{"orgOrder":0,"company":"Hillhurst Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Carbon Monoxide","moa":"HO metabolic pathway","graph1":"Hematology","graph2":"Phase I","graph3":"Hillhurst Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hillhurst Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hillhurst Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Cellphire Therapeutics","sponsor":"Simcah Management","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"April 2021","year":"2021","type":"Series A Financing","leadProduct":"Platelet-based freeze-dried hemostatic agent","moa":"","graph1":"Hematology","graph2":"Phase II","graph3":"Cellphire Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellphire Therapeutics \/ Simcah Management","highestDevelopmentStatusID":"8","companyTruncated":"Cellphire Therapeutics \/ Simcah Management"},{"orgOrder":0,"company":"Nemysis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Iron Hydroxide Adipate Tartrate","moa":"Iron","graph1":"Hematology","graph2":"Phase II","graph3":"Nemysis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nemysis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nemysis \/ Not Applicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"M.D. Anderson Cancer Center","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Daiichi Sankyo \/ M.D. Anderson Cancer Center","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sankyo \/ M.D. Anderson Cancer Center"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"SFJ Pharmaceuticals","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Peptide","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ SFJ Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ SFJ Pharmaceuticals"},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin-associated serine protease 2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Not Applicable"},{"orgOrder":0,"company":"Western New England University","sponsor":"Quercis Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","date":"May 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Zafirlukast","moa":"Thiol isomerase","graph1":"Hematology","graph2":"Phase II","graph3":"Western New England University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Western New England University \/ Quercis Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Western New England University \/ Quercis Pharma"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imago BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Peptide","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Sobi","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Sobi"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Drogsan Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"June 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Ferric Pyrophosphate Citrate","moa":"Transferrin","graph1":"Hematology","graph2":"Approved","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Rockwell Medical \/ Drogsan Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Rockwell Medical \/ Drogsan Pharmaceuticals"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imago BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"MASP-2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Not Applicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Iodine-131 Apamistamab","moa":"CD45","graph1":"Hematology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Busulfan","moa":"CD34+ gene","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blood Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"Factor B","graph1":"Hematology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Alfasigma","pharmaFlowCategory":"D","upfrontCash":"$20.0 million","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"June 2021","year":"2021","type":"Acquisition","leadProduct":"Bentracimab","moa":"P2Y12 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0.25,"dosageForm":"Intravenous Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Alfasigma","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ Alfasigma"},{"orgOrder":0,"company":"Veralox Therapeutics","sponsor":"Hatteras Venture","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"June 2021","year":"2021","type":"Series A Financing","leadProduct":"VLX-1005","moa":"12-LOX","graph1":"Hematology","graph2":"Phase I","graph3":"Veralox Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Veralox Therapeutics \/ Hatteras Venture","highestDevelopmentStatusID":"6","companyTruncated":"Veralox Therapeutics \/ Hatteras Venture"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ FibroGen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ FibroGen"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rockwell Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rockwell Medical \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"WuXi Biologics","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"CAN106","moa":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"CANbridge Pharmaceuticals \/ WuXi Biologics","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge Pharmaceuticals \/ WuXi Biologics"},{"orgOrder":0,"company":"Hemab Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"July 2021","year":"2021","type":"Series A Financing","leadProduct":"Monoclonal-bispecific Antibody-based Therapeutics","moa":"","graph1":"Hematology","graph2":"Undisclosed","graph3":"Hemab Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Hemab Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"1","companyTruncated":"Hemab Therapeutics \/ Novo Holdings"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Daprodustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"FibroGen","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ FibroGen"},{"orgOrder":0,"company":"AustinPx","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Deferasirox","moa":"Iron","graph1":"Hematology","graph2":"Phase II","graph3":"AustinPx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AustinPx \/ Catalent","highestDevelopmentStatusID":"8","companyTruncated":"AustinPx \/ Catalent"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imago BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Bentracimab","moa":"P2Y12 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ Astellas Pharma","highestDevelopmentStatusID":"12","companyTruncated":"FibroGen \/ Astellas Pharma"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blood Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"C5 complement","graph1":"Hematology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Premier","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin III","graph1":"Hematology","graph2":"Undisclosed","graph3":"Meitheal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Meitheal Pharmaceuticals \/ Premier Inc","highestDevelopmentStatusID":"1","companyTruncated":"Meitheal Pharmaceuticals \/ Premier Inc"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Mepolizumab","moa":"IL-5","graph1":"Hematology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Norgine","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ciraparantag","moa":"","graph1":"Hematology","graph2":"Phase II","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Covis Pharma \/ Norgine B.V.","highestDevelopmentStatusID":"8","companyTruncated":"Covis Pharma \/ Norgine B.V."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Peptide","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Hematology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Peptide","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Lowell Therapeutics","sponsor":"AcelRx Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"November 2021","year":"2021","type":"Acquisition","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Hematology","graph2":"Undisclosed","graph3":"Lowell Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lowell Therapeutics \/ AcelRx Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Lowell Therapeutics \/ AcelRx Pharmaceuticals"},{"orgOrder":0,"company":"GSK","sponsor":"","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Daprodustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ ","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ "},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Bentracimab","moa":"P2Y12 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rockwell Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rockwell Medical \/ Not Applicable"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Bentracimab","moa":"P2Y12 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blood Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"OMERS Capital Market","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"November 2021","year":"2021","type":"Financing","leadProduct":"BCX9930","moa":"Complement Factor D","graph1":"Hematology","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.34999999999999998,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ OMERS Capital Market","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst Pharmaceuticals \/ OMERS Capital Market"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Desidustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Phase I","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"BCX9930","moa":"Complement Factor D","graph1":"Hematology","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CSL","pharmaFlowCategory":"D","upfrontCash":"$11,700.0 million","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"CSL Vifor","amount2":11.699999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":11.699999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Vifor \/ CSL","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ CSL"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"December 2021","year":"2021","type":"Public Offering","leadProduct":"Voxelotor","moa":"HbA positive","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0.29999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0.29999999999999999,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Global Blood Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Peptide","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Sobi ","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Sobi "},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rockwell Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rockwell Medical \/ Not Applicable"},{"orgOrder":0,"company":"VarmX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"VMX-C001","moa":"Factor Xa","graph1":"Hematology","graph2":"Preclinical","graph3":"VarmX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"VarmX \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VarmX \/ Not Applicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blood Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blood Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird Bio \/ Not Applicable"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imago BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"BCX9930","moa":"Complement Factor D","graph1":"Hematology","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Busulfan","moa":"CD34+ gene","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"NM8074","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"NovelMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"NovelMed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NovelMed Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blood Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"CAN106","moa":"Complement C5","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"D","upfrontCash":"$25.0 million","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"February 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blood Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Daprodustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Bentracimab","moa":"P2Y12 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Hematology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CAN106","moa":"Completent C5","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"Glutathione","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Hematology","graph2":"Phase II","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AcelRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Andexanet Alfa","moa":"Factor Xa","graph1":"Hematology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Bentracimab","moa":"P2Y12 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BCX9930","moa":"Complement Factor D","graph1":"Hematology","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Daprodustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin-associated serine protease-2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Not Applicable"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Coagulation Factor X (Human)","moa":"Factor Xa","graph1":"Hematology","graph2":"Approved","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Products Laboratory \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bio Products Laboratory \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Rallybio","pharmaFlowCategory":"D","upfrontCash":"$3.0 million","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"May 2022","year":"2022","type":"Licensing Agreement","leadProduct":"RLYB331","moa":"Matriptase-2","graph1":"Hematology","graph2":"Preclinical","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sanofi \/ Rallybio Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ Rallybio Corporation"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Peptide","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"STP122G","moa":"Factor XI expression","graph1":"Hematology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Peptide","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Imago BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Desidustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Bentracimab","moa":"P2Y12 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"KER-012","moa":"SMAD 2\/3","graph1":"Hematology","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Keros Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CAN106","moa":"Complement C5","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aucta Pharmaceuticals","sponsor":"Oakrum Pharma, LLC","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Deferasirox","moa":"Iron","graph1":"Hematology","graph2":"Approved","graph3":"Aucta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Granule","sponsorNew":"Aucta Pharmaceuticals \/ Oakrum Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Aucta Pharmaceuticals \/ Oakrum Pharma"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Kashiv BioSciences","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"Hematopoietic Cell","graph1":"Hematology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amneal Pharmaceuticals \/ Kashiv Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pharmaceuticals \/ Kashiv Biosciences"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Not Applicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Hematology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Peptide","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Apellis Pharmaceuticals \/ Sobi","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Sobi"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blood Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CAN106","moa":"Completent C5","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Not Applicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"CDK4\/CDK6","graph1":"Hematology","graph2":"Phase II","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"G1 Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"SCB-219M","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Danone","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Iron","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Danone","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Dry Powder","sponsorNew":"Danone \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Danone \/ Not Applicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"STP122G","moa":"Factor XI expression","graph1":"Hematology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Not Applicable"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Brand Institute","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kashiv BioSciences \/ Brand Institute","highestDevelopmentStatusID":"12","companyTruncated":"Kashiv BioSciences \/ Brand Institute"},{"orgOrder":0,"company":"Spherix Global Insights","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Spherix Global Insights","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spherix Global Insights \/ Astellas","highestDevelopmentStatusID":"12","companyTruncated":"Spherix Global Insights \/ Astellas"},{"orgOrder":0,"company":"American Regent","sponsor":"Provepharm Life Solutions","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Methylene Blue","moa":"Methemoglobin","graph1":"Hematology","graph2":"Approved","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"American Regent \/ Provepharm Life Solution","highestDevelopmentStatusID":"12","companyTruncated":"American Regent \/ Provepharm Life Solution"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"CAN106","moa":"Completent C5","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius Kabi AB Brunna \/ Not Applicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbS polymerization","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blood Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Busulfan","moa":"CD34+ gene","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"JAK1","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Solution for Injection in Pre-filled Injector","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Not Applicable"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Nulabeglogene Autogedtemcel","moa":"CRISPR\/HiFi Cas9 gene","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Graphite Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Daprodustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius Kabi AB Brunna \/ Not Applicable"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Zydus Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"September 2022","year":"2022","type":"Acquisition","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Approved","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pharmacosmos AS \/ Zydus","highestDevelopmentStatusID":"12","companyTruncated":"Pharmacosmos AS \/ Zydus"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"Nomacopan","moa":"Completent C5","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Akari Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Eflapegrastim","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Spectrum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Not Applicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4","graph1":"Hematology","graph2":"Phase I","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"X4 Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","upfrontCash":"$5,400.0 million","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"Voxelotor","moa":"HbA positive","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":5.4000000000000004,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":5.4000000000000004,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Global Blood Therapeutics \/ Pfizer"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","upfrontCash":"$1,100.0 million","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"Etavopivat","moa":"PKR","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":1.1000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":1.1000000000000001,"dosageForm":"Tablet","sponsorNew":"Forma Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"JSR Life Sciences","sponsor":"Blau Farmaceutica","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"October 2022","year":"2022","type":"Partnership","leadProduct":"Epoetin Alfa","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"JSR Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"JSR Life Sciences \/ Blau Farmaceutica","highestDevelopmentStatusID":"12","companyTruncated":"JSR Life Sciences \/ Blau Farmaceutica"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Daprodustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Daprodustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"MGTA-145","moa":"CXCR2","graph1":"Hematology","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Magenta Therapeutics \/ bluebird bio","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Therapeutics \/ bluebird bio"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"KER-047","moa":"ALK-2","graph1":"Hematology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AG-946","moa":"","graph1":"Hematology","graph2":"Phase II","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agios Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"DISC-0998","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Preclinical","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Disc medicine \/ Not Applicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"NovaQuest Capital Management","pharmaFlowCategory":"D","upfrontCash":"$50.0 million","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"November 2022","year":"2022","type":"Financing","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"FibroGen","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ NovaQuest Capital Management","highestDevelopmentStatusID":"12","companyTruncated":"FibroGen \/ NovaQuest Capital Management"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Polifarma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Darbepoetin alfa","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Dong-A ST Co., Ltd. \/ Polifarma","highestDevelopmentStatusID":"12","companyTruncated":"Dong-A ST Co., Ltd. \/ Polifarma"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase","graph1":"Hematology","graph2":"Approved","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Agios Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Coagulant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"CT-001","moa":"","graph1":"Hematology","graph2":"IND Enabling","graph3":"Coagulant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Coagulant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Coagulant Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Filgrastim","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Avapritinib","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Evive Biotech","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Benegrastim","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aurobindo Pharma Limited \/ Evive Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Aurobindo Pharma Limited \/ Evive Biotech"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"X4 Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Piper Sandler","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Mavorixafor","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"X4 Pharmaceuticals \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"X4 Pharmaceuticals \/ Piper Sandler"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Piper Sandler","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Mavorixafor","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"X4 Pharmaceuticals","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"X4 Pharmaceuticals \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"X4 Pharmaceuticals \/ Piper Sandler"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Busulfan","moa":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Peptide","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apellis Pharmaceuticals \/ Sobi","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Sobi"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"KER-047","moa":"","graph1":"Hematology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Plinabulin","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Not Applicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"GCSF","graph1":"Hematology","graph2":"Approved","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kashiv BioSciences \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Kashiv BioSciences \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Nulabeglogene Autogedtemcel","moa":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Graphite Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Avapritinib","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"SFJ Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Bentracimab","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ SFJ Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ SFJ Pharmaceuticals"},{"orgOrder":0,"company":"Mabwell","sponsor":"Disc medicine","pharmaFlowCategory":"D","upfrontCash":"$10.0 million","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"MWTX-001","moa":"","graph1":"Hematology","graph2":"IND Enabling","graph3":"Mabwell","amount2":0.40999999999999998,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Mabwell \/ DISC MEDICINE","highestDevelopmentStatusID":"5","companyTruncated":"Mabwell \/ DISC MEDICINE"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Tecarfarin","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cadrenal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cadrenal Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Avapritinib","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"CRISPR Therapeutics","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ CRISPR Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pharmaceuticals \/ CRISPR Therapeutics"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Eflapegrastim","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Spectrum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","upfrontCash":"$75.0 million","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"PBGENE-HbE","moa":"","graph1":"Hematology","graph2":"Discovery","graph3":"Precision BioSciences","amount2":1.48,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hematology","amount2New":1.48,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Precision BioSciences \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","upfrontCash":"$5,400.0 million","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"Voxelotor","moa":"HbA positive","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":5.4000000000000004,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":5.4000000000000004,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Global Blood Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","upfrontCash":"$1,100.0 million","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","date":"September 2022","year":"2022","type":"Acquisition","leadProduct":"Etavopivat","moa":"PKR","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":1.1000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":1.1000000000000001,"dosageForm":"Tablet","sponsorNew":"Forma Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","upfrontCash":"$1,350.0 million","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"Bomedemstat","moa":"","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":1.3500000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":1.3500000000000001,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Merck & Co. Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Merck & Co. Inc."},{"orgOrder":0,"company":"Garuda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"February 2023","year":"2023","type":"Series B Financing","leadProduct":"Blood Stem cell-based Therapy","moa":"","graph1":"Hematology","graph2":"Preclinical","graph3":"Garuda Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Garuda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Garuda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Merck Group","pharmaFlowCategory":"D","upfrontCash":"$1,350.0 million","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"Bomedemstat","moa":"","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":1.3500000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":1.3500000000000001,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Merck"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Avapritinib","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Nomacopan","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Hemab Therapeutics","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"February 2023","year":"2023","type":"Series B Financing","leadProduct":"HMB-001","moa":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Hemab Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0.14000000000000001,"dosageForm":"Capsule","sponsorNew":"Hemab Therapeutics \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"Hemab Therapeutics \/ Deep Track Capital"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"J.P. Morgan Securities LLC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Peptide","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"Pegcetacoplan","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0.34999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0.34999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Apellis Pharmaceuticals \/ J.P. Morgan Securities LLC","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ J.P. Morgan Securities LLC"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Peptide","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"Pegcetacoplan","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0.40000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0.40000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"Apellis Pharmaceuticals \/ J.P. Morgan Securities","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ J.P. Morgan Securities"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Peptide","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Motixafortide","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioLineRx \/ Washington University School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"BIOSYENT PHARMA INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Polydextrose Iron Complex","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"BIOSYENT PHARMA INC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BIOSYENT PHARMA INC \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BIOSYENT PHARMA INC \/ Not Applicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Paulson Investment Company","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Nomacopan","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Akari Therapeutics \/ Paulson Investment Company","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Paulson Investment Company"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Nomacopan","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Nomacopan","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"CRISPR Therapeutics","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ CRISPR Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pharmaceuticals \/ CRISPR Therapeutics"},{"orgOrder":0,"company":"Reachbio Research Labs","sponsor":"Discovery Life Sciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"April 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Hematology","graph2":"Discovery","graph3":"Reachbio Research Labs","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Reachbio Research Labs \/ Discovery Life Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Reachbio Research Labs \/ Discovery Life Sciences"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Argatroban","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","upfrontCash":"$291.0 million","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"April 2023","year":"2023","type":"Acquisition","leadProduct":"Eflapegrastim-xnst","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Spectrum Pharmaceuticals","amount2":0.76000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0.76000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Assertio Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Spectrum Pharmaceuticals \/ Assertio Therapeutics"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird Bio \/ Not Applicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"OMS906","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Omeros \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Busulfan","moa":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Roxadustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"FibroGen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"FibroGen \/ Not Applicable"},{"orgOrder":0,"company":"SFJ Pharmaceuticals","sponsor":"Serb","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"May 2023","year":"2023","type":"Acquisition","leadProduct":"Bentracimab","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"SFJ Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SFJ Pharmaceuticals \/ SERB","highestDevelopmentStatusID":"10","companyTruncated":"SFJ Pharmaceuticals \/ SERB"},{"orgOrder":0,"company":"Microbix Biosystems","sponsor":"Sequel Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"Urokinase","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Microbix Biosystems","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Microbix Biosystems \/ Sequel Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Microbix Biosystems \/ Sequel Pharma"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Kashiv BioSciences","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegfilgrastim-pbbk","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amneal Pharmaceuticals \/ Kashiv Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pharmaceuticals \/ Kashiv Biosciences"},{"orgOrder":0,"company":"Lobe Sciences","sponsor":"Pentec Health","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"DHA","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Lobe Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lobe Sciences \/ Pentec Health","highestDevelopmentStatusID":"12","companyTruncated":"Lobe Sciences \/ Pentec Health"},{"orgOrder":0,"company":"Emcure Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Emcure Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Emcure Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emcure Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Roxadustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"FibroGen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"FibroGen \/ Not Applicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Avapritinib","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Endo International","sponsor":"MAIA Biotechnology","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Peptide","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"Bivalirudin","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Endo International \/ MAIA Biotechnology","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ MAIA Biotechnology"},{"orgOrder":0,"company":"Hillhurst Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Carbon Monoxide","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"Hillhurst Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Hillhurst Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hillhurst Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Medice Arzneimittel P\u00fctter GmbH&Co.KG","pharmaFlowCategory":"D","upfrontCash":"$10.0 million","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Vadadustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0.11,"dosageForm":"","sponsorNew":"Akebia Therapeutics \/ Medice Arzneimittel P\u00fctter GmbH&Co.KG","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Medice Arzneimittel P\u00fctter GmbH&Co.KG"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Crizanlizumab-tmca","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"STP122G","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Not Applicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"American Regent","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Daiichi Sankyo \/ American Regent","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sankyo \/ American Regent"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CSL","pharmaFlowCategory":"D","upfrontCash":"$11,700.0 million","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"CSL Vifor","amount2":11.699999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":11.699999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"CSL Vifor \/ CSL","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ CSL"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird Bio \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Daprodustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Mitapivat","moa":"","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Agios Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Nemysis","sponsor":"Bruno Farmaceutici","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"Iron Hydroxide Adipate Tartrate","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Nemysis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nemysis \/ Bruno Farmaceutici","highestDevelopmentStatusID":"12","companyTruncated":"Nemysis \/ Bruno Farmaceutici"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Nomacopan","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Velico Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Plasma","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"Velico Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Velico Medical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Velico Medical \/ Not Applicable"},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","upfrontCash":"$40.0 million","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"July 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Ex-vivo NK Cell Therapy","moa":"","graph1":"Hematology","graph2":"Preclinical","graph3":"Scribe Therapeutics","amount2":1.24,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":1.24,"dosageForm":"","sponsorNew":"Scribe Therapeutics \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Scribe Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Peptide","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Bivalirudin","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Nomacopan","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"July 2023","year":"2023","type":"Private Placement","leadProduct":"Nafamostat","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"AcelRx Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"AcelRx Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"AcelRx Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Azzur Group","sponsor":"Editas Medicine","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"July 2023","year":"2023","type":"Partnership","leadProduct":"EDIT-301","moa":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Azzur Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Azzur Group \/ Editas Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Azzur Group \/ Editas Medicine"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Nomacopan","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Crizanlizumab","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird Bio \/ Not Applicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Bluebird Bio","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"MGTA-145","moa":"","graph1":"Hematology","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Magenta Therapeutics \/ bluebird bio","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Therapeutics \/ bluebird bio"},{"orgOrder":0,"company":"American Regent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"American Regent \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"American Regent \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"Hillhurst Biopharmaceuticals","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"September 2023","year":"2023","type":"Funding","leadProduct":"Carbon Monoxide","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"Hillhurst Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Hillhurst Biopharmaceuticals \/ National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"6","companyTruncated":"Hillhurst Biopharmaceuticals \/ National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Peptide","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Nafamostat","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AcelRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Busulfan","moa":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"October 2023","year":"2023","type":"Financing","leadProduct":"Lovotibeglogene Autotemcel","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Bluebird Bio","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird Bio \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Desidustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Enarodustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Not Applicable"},{"orgOrder":0,"company":"RoslinCT","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Exagamglogene Autotemcel","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"RoslinCT","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RoslinCT \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"RoslinCT \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Minapharm Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"December 2023","year":"2023","type":"Agreement","leadProduct":"Enoxaparin Sodium","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Minapharm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Minapharm Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Minapharm Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Avapritinib","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Avapritinib","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Exagamglogene Autotemcel","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Editas Medicine \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Editas Medicine \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Exagamglogene Autotemcel","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Charles River Laboratories, Inc \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Charles River Laboratories, Inc \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Elritercept","moa":"","graph1":"Hematology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Elritercept","moa":"","graph1":"Hematology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Kolinpharma","sponsor":"Nemysis","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"January 2024","year":"2024","type":"Agreement","leadProduct":"Iron Hydroxide Adipate Tartrate","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Kolinpharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kolinpharma \/ Nemysis","highestDevelopmentStatusID":"12","companyTruncated":"Kolinpharma \/ Nemysis"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"GMI-1687","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GlycoMimetics \/ Not Applicable"},{"orgOrder":0,"company":"Ainos","sponsor":"Lind Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"January 2024","year":"2024","type":"Financing","leadProduct":"Interferon Alfa","moa":"","graph1":"Hematology","graph2":"Phase II","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Lind Partners","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ Lind Partners"},{"orgOrder":0,"company":"Avenacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Peptide","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Bivalirudin","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avenacy \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avenacy \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Nipocalimab","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Hercules Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"March 2024","year":"2024","type":"Financing","leadProduct":"Lovotibeglogene Autotemcel","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Hercules Capital","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird Bio \/ Hercules Capital"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Inclacumab","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"DanausGT Biotechnology","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Hematology","graph2":"Preclinical","graph3":"Porton Advanced Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Porton Advanced Solutions \/ DanausGT Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Porton Advanced Solutions \/ DanausGT Biotechnology"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Medicaid","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"March 2024","year":"2024","type":"Agreement","leadProduct":"Lovotibeglogene Autotemcel","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Medicaid","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird Bio \/ Medicaid"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CRISPR Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CRISPR Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CRISPR Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CRISPR Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"SCB-219M","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Momelotinib","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"BT524","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Not Applicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Kamau Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"December 2023","year":"2023","type":"Agreement","leadProduct":"Nulabeglogene Autogedtemcel","moa":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Graphite Bio \/ Kamau Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Kamau Therapeutics"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Bluebird Bio","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pharmaceuticals \/ Bluebird Bio"},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"8MW0511","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mabwell \/ Not Applicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Peptide","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Motixafortide","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx \/ Not Applicable"},{"orgOrder":0,"company":"Nora Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Nora Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nora Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nora Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ainos","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"May 2024","year":"2024","type":"Financing","leadProduct":"Interferon Alfa","moa":"","graph1":"Hematology","graph2":"Phase II","graph3":"Ainos","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.01,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ Undisclosed"},{"orgOrder":0,"company":"BioLineRx","sponsor":"St. Jude Children's Research Hospital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Peptide","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"Motixafortide","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"BioLineRx \/ St. Jude Children's Research Hospital","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx \/ St. Jude Children's Research Hospital"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Ethypharm","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Acquisition","leadProduct":"Argatroban Monohydrate","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Mitsubishi Tanabe Pharma \/ Ethypharm","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi Tanabe Pharma \/ Ethypharm"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"X4 Pharmaceuticals \/ Not Applicable"}]

    Find Hematology Clinical Drug Pipeline Developments & Deals

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanofi

                            France
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : RLYB331

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Sponsor : Rallybio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi

                            Details : Rallybio plans to prosecute preclinical activities for KY1066/RLYB331 including CMC, and dose-range finding and toxicity studies, which will then support transition of the asset into clinical development.

                            Brand Name : KY1066

                            Molecule Type : Large molecule

                            Upfront Cash : $3.0 million

                            May 10, 2022

                            Lead Product(s) : RLYB331

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Sponsor : Rallybio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aucta Pharmaceuticals

                            U.S.A
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothAucta is a global brand that creates better products from proven molecules.

                            Lead Product(s) : Deferasirox

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : Oakrum Pharma, LLC

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oakrum Pharma and Aucta Pharma Announce U.S. FDA Approval of Generic Version of JADENU® Sprinkle (Deferasirox...

                            Details : JADENU (deferasirox) tablets for oral use and JADENU® Sprinkle (deferasirox) granules are indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.

                            Brand Name : Jadenu

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 22, 2021

                            Lead Product(s) : Deferasirox

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : Oakrum Pharma, LLC

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Aucta Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Prime Medicine

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Prime Medicine

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : T-Cell Therapy

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $3,610.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Prime Medicine and Bristol Myers Partner On Ex Vivo T-Cell Therapies

                            Details : The collaboration combines Prime Medicine’s precise, multiplex gene editing capabilities with BMS’s broad expertise in development and commercialization of novel ex vivo T-cell therapies.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 30, 2024

                            Lead Product(s) : T-Cell Therapy

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $3,610.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lupin Ltd

                            India arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Lupin Ltd

                            India arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegfilgrastim

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lupin Gains Health Canada Approval for Biosimilar Pegfilgrastim

                            Details : Armlupeg (pegfilgrastim) is a biosimilar of Neulasta, that acts as a G-CSF agonist & it is indicated for the treatment of patients suffering from febrile neutropenia.

                            Brand Name : Armlupeg

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 23, 2024

                            Lead Product(s) : Pegfilgrastim

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Veralox Therapeutics

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Veralox Therapeutics

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VLX-1005

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Veralox Therapeutics Announces EMA Orphan Drug Designation for VLX-1005

                            Details : VLX-1005, a small molecule 12-LOX inhibitor, which is being evaluated for the treatment of heparin induced thrombocytopenia.

                            Brand Name : VLX-1005

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 14, 2024

                            Lead Product(s) : VLX-1005

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cadrenal Therapeutics

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Cadrenal Therapeutics

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tecarfarin

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Abbott Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Cadrenal and Abbott Collaborate on Novel Anticoagulant Tecarfarin for LVAD Patients

                            Details : The collaboration aims to advance the novel anticoagulant ATI-5923 (tecarfarin), designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with implanted cardiac devices.

                            Brand Name : ATI-5923

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 06, 2024

                            Lead Product(s) : Tecarfarin

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Abbott Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Octapharma

                            Switzerland arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Octapharma

                            Switzerland arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fibrinogen

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Approves Fibryga® for Fibrinogen Supplementation in Acquired Deficiency

                            Details : Fibryga is a fibrinogen concentrate which acts as as fibrinogen replacement therapy. It is approved for the treatment of acquired fibrinogen deficiency (AFD).

                            Brand Name : Fibryga

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 01, 2024

                            Lead Product(s) : Fibrinogen

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            X4 Pharmaceuticals

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            X4 Pharmaceuticals

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mavorixafor

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            X4 Pharmaceuticals Reports Positive Interim Data in Chronic Neutropenia Trial

                            Details : Xolremdi (mavorixafor) is a selective CXCR4 antagonist, which is being evaluated for the treatment of idiopathic chronic neutropenic disorders who are experiencing recurrent &/​or serious infections.

                            Brand Name : Xolremdi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 27, 2024

                            Lead Product(s) : Mavorixafor

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Mitsubishi Tanabe Pharma

                            Japan arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Mitsubishi Tanabe Pharma

                            Japan arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Argatroban Monohydrate

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : Ethypharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Acquisition of Argatroban Business in Europe

                            Details : Ethypharm acquired Mitsubishi Tanabe's selective antithrombin agent Arganova (argatroban monohydrate) in Europe. It is indicated for the treatment of heparin-induced thrombocytopenia type II.

                            Brand Name : Arganova

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 17, 2024

                            Lead Product(s) : Argatroban Monohydrate

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : Ethypharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Ainos

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Ainos

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interferon Alfa

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $9.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Ainos Raises $9 Million in Growth Capital with Existing Shareholder

                            Details : The financing will be used to advance company's products including VELDONA (interferon alfa) which binds to type I interferon receptors (IFNAR). It is being evaluated for thrombocytopenia.

                            Brand Name : Veldona

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 07, 2024

                            Lead Product(s) : Interferon Alfa

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $9.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth